Mimvey — Class III drug recall D-0522-2022
Terminated recall by Teva Pharmaceuticals USA, reported 2022-02-09, distributed nationwide. Mislabeling
| Recall number | D-0522-2022 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Parsippany, NJ, United States |
| Recall initiated | 2022-01-07 |
| Classified | 2022-02-02 |
| Reported by FDA | 2022-02-09 |
| Terminated | 2023-06-01 |
| Distributed | Nationwide (US) |
| Quantity | 6,430 cartons |
| Reason classes | labeling |
| NDC | 00093-5455, 00093-5455-28, 00093-5455-42 |
| Lot numbers | 100018610, 100021521, 100024575 |
| Expiration dates | 2022-03, 2022-09, 2023-01 |
Product
Mimvey (estradiol and norethindrone acetate tablets USP) 1 mg/0.5 mg, packaged in cartons of 28 Tablets, Rx Only, Manufactured By: Barr Laboratories, Inc., Pomona, NY 10970, Manufactured For: Teva Pharmaceuticals USA Inc. North Wales, PA 19454, NDC 0093-5455-42
Reason for recall
Mislabeling
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0522-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.